id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0018-0054,FDA,FDA-1977-N-0018,"Memorandum of Meeting Between FDA/CDER and Bayer HealthCare dated November 19, 2003",Other,Memorandum,2003-12-09T05:00:00Z,2003,12,,,2019-02-04T17:13:11Z,,0,0,09000064805d99ab
FDA-1977-N-0018-0053,FDA,FDA-1977-N-0018,"Memorandum between Representatives of FDA and Bayer HealthCare, LLC",Other,Memorandum,2003-11-12T05:00:00Z,2003,11,,,2019-02-04T17:15:11Z,,0,0,09000064805d99aa
FDA-1977-N-0018-0052,FDA,FDA-1977-N-0018,Internal Memorandum from Charles J Ganley (HFD-560) to FDA/DDM (HFA-305) August 8 2003,Other,Memorandum,2003-08-22T04:00:00Z,2003,8,,,2019-02-01T14:33:27Z,,0,0,09000064805d99a3
FDA-1977-N-0018-0051,FDA,FDA-1977-N-0018,"Letter from FDA/CDER to Bayer HealthCare, LLC",Other,Letter(s),2003-08-22T04:00:00Z,2003,8,,,2019-01-28T21:43:10Z,,0,0,09000064805d99a2